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Case presentations
Patient 1. A 34-year-old black man presented to the Emergency Room
of Columbia-Presbyterian Medical Center complaining of weakness, an-
orexia, and nausea of several weeks duration, and edema of the legs for 2
days. In the Emergency Room, his BUN was 80 mg/dl and the serum
creatinine was 16.3 mgldl; he was admitted for further evaluation.
The medical history was notable for an 8-year history of hypertension,
treated only for 4 months with a diuretic. A "kidney infection" was treated
2 years prior to admission with oral antibiotics. There was no known
history of diabetes, sickle-cell disease, or nephrolithiasis. His sister had
recurrent "kidney infections" and his father died at age 70 from renal
failure. The patient worked full-time as a taxi driver and youth counselor.
He used nasal cocaine, but denied intravenous drug use or homosexual
contacts.
The admission physical examination revealed: blood pressure 150—170/
110—120 mm Hg, grade-i hypertensive retinopathy, a grade Il/VI systolic
ejection murmur, scrotal and penile edema, a penile discharge, and 2+
edema of the lower extremities. Laboratory data included: hematocrit,
35.5%; white blood cell count, 8900 mm3; erythrocyte sedimentation rate,
123 mm/hr; serum creatinine, 16 ing/dI; and BUN, 80 mg/dl. Urinalysis
revealed: 3+ protein; 20—25 white blood cells and 0—1 red blood
cells/high-power field; and no casts. Serum albumin was 1.2 gIdl; total
protein, 4.7 g/dl; and cholesterol, 390 mg/dl. A renal ultrasound examina-
tion disclosed hyperechoic kidneys. On nephrotomography, the left kidney
measured 12 cm and the right, 11 cm. A 24-hour urine collection
contained 36.5 g of protein, and the creatinine clearance was 5 cc/mm.
Titers for antinuclear antibodies; latex fixation; cryoglobulins; hepatitis B
surface antigen and antibody; and serum complement all were negative or
normal. Tests for syphilis (Veneral Disease Research Laboratory, VDRL,
test and fluorescent treponemal antibody, FTA test) were positive, and a
urethral culture grew gonococcus; HIV serologies were obtained. The
patient was treated with procaine penicillin for acute gonorrhea and
The Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated; Marion Merrell Dow, Incor-
porated; Dialysis Clinic, Incorporated; and R & D Laboratories,
Incorporated.
© 1994 by the International Society of Nephrology
benzathine penicillin (times 3) for latent syphilis. An open renal biopsy
was performed (Fig. 1).
The renal biopsy disclosed that 60% of the 150 glomeruli were globally
sclerotic. Another 25% displayed segmental to global collapse of the
glomerular tuft without a significant increase in mesangial or intracapillary
matrix. The visceral epithelial cells were markedly hypertrophied and
contained numerous intracytoplasmic hyaline droplets. The specimen
showed severe diffuse tubular atrophy, interstitial fibrosis, and edema with
focal tubular "microcysts," and widespread tubular degenerative and
regenerative changes. Fluorescence microscopy disclosed 3 + segmental to
global coarse glomerular staining for C3 and 1 + staining for 1gM. On
electron microscopy, non-sclerotic capillaries showed widespread wrin-
kling of the glomerular basement membranes with 100% foot process
fusion. A single small endothelial tubuloreticular inclusion was identified
in one glomerular capillary. A diagnosis of idiopathic focal segmental
glomerulosclerosis, collapsing variant, was made.
After the biopsy, a diuresis was induced with intravenous furosemide.
The patient was given methylprednisolone intravenously, 1 g for 3 days,
followed by prednisone, 120 mg every other day. His proteinuria did not
respond to a 4-week course of steroids, and 3 weeks following biopsy,
hemodialysis was initiated for his end-stage renal failure. The patient has
done well on dialysis for 5 years; he is not considered a candidate for
transplantation because of his cocaine use. HIV titers performed annually
for 5 years have been negative.
Patient 2. A 44-year-old massively obese (380 lb) white man with sleep
apnea was referred to Columbia-Presbyterian Medical Center for workup
of proteinuria. His history was notable for an atrophic left testicle and
undescended right testicle; hypogonadism had been treated with methyl-
testosterone for 23 years. Ten years prior to admission, he experienced a
single episode of gross hematuria. A urologic workup was negative, and he
had no subsequent recurrences. He had no history of hypertension,
diabetes, or other systemic disease. An episode of cellulitis of the right leg
resolved with antibiotic therapy one year prior to admission.
On evaluation, the blood pressure was 150/92 mm Hg and he had 1+
edema of the lower extremities. Laboratory workup disclosed: serum
creatinine, 1.1 mg/dl; BUN, 19 mg/dl; cholesterol, 313 mgldl; total protein,
7.7 g/dl; serum albumin, 4.2 g/dl; and hematocrit, 52%. Blood glucose,
urine protein electrophoresis, serum protein electrophoresis, C3, C4,
CH50, hepatitis serologies, ANA and cryoglobulins all were negative or
normal. Urinalysis disclosed: specific gravity, 1.030; 3+ albumin; 2+
heme; and rare red blood cell casts. Urinary protein excretion was 4.9 g/24
hrs. The kidneys measured 14 to 15 cm by ultrasound.
A renal biopsy was performed (Fig. 2). The biopsy specimen contained
19 glomeruli, of which 2 were globally sclerotic and 3 segmentally sclerotic.
Segmental lesions were discrete, located at the vascular pole, with
increased matrix and Bowman's capsular adhesion. Visceral epithelial
cells showed little or no hyperplasia. Nonsclerotic glomeruli were mark-
edly enlarged (glomerular diameter 150% of normal), consistent with
glomerular hypertrophy, and there was focal hyperplasia of the juxtaglo-
merular apparatus. Several small foci of tubular atrophy and interstitial
fibrosis were present, and mild arteriolosclerosis was apparent. Immuno-
fluorescence microscopy disclosed segmental to global glomerular staining
in areas of sclerosis for C3 only. On electron microscopic study, the only
abnormality was minimal foot process fusion affecting approximately 20%
of the glomerular capillary surface area. A diagnosis of secondary focal
segmental glomeruloscierosis related to morbid obesity with sleep apnea
was made.
The patient was advised to lose weight. Enalapril, 5 mg/day, was
prescribed, and he was given therapy for sleep apnea. Eight months after
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Fig. 1. A Biopsy specimen from Patient 1. Four
glomeruli with diffuse and global retraction
("collapse") of the glomerular tuft are
illustrated. Widespread tubular degenerative
changes are apparent. (Jones methenamine
silver, X 100.)
Fig. 1. B Collapsing glomeruloscierosis in biopsy
specimen from Patient 1. Note marked swelling
and hyperplasia of visceral epithelial cells,
occlusion of many capillary luinina, but no
obvious increase in matrix. (Jones methenainine
silver, X 250.)
the biopsy, the urinary protein had decreased to 2.0 glday, with resolution
of edema and stable renal function.
Discussion
DR. VIvErrn D'AGATI (Director, Renal Pathology Laboratoty,
and Associate Professor of Pathology, College of Physicians and
Surgeons of Columbia University, New York, New York): Focal
segmental glomeruloscierosis is one of the most common and
nonspecific patterns of glomerular injury encountered in human
renal biopsies. Only some cases represent idiopathic focal seg-
mental glomerulosclerosis, the primary disease entity associated
with the nephrotic syndrome [1—3]. Many prove to be secondary
forms in which glomeruli become sclerosed in the course of
adaptive structural-functional alterations that follow loss of func-
tioning nephrons, hyperfiltration, or other hemodynamic stresses.
Yet other cases represent a pattern of focal segmental glomeru-
loscierosis caused by the scarring that follows inflammatory,
proliferative, thrombotic, hereditary, or other glomerular injuries
[4]. Distinguishing among these primary and secondary forms
often poses a particular challenge to the nephropathologist (Table
1). Proper classification is not merely pedantic but has important
clinical implications for prognosis and therapy. A correct diagno-
sis can only be made following complete renal biopsy evaluation
to exclude underlying renal diseases, and after close communica-
tion with the clinician to integrate detailed information regarding
the existence of previous renal disease, systemic conditions, level
of proteinuria, and other renal manifestations.
Diagnosing primary (idiopathic) focal segmental glomeruloscle-
rosis by biopsy is particularly problematic because no universally
accepted morphologic or clinical criteria for the diagnosis exist.
Each of the pathologic features is in itself nonspecific and can
occur in a variety of other conditions or can be superimposed on
other glomerular processes. Moreover, because the lesion is focal,
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Fig. 2. A Biopsy specimen from Patient 2. Four
hypertrophied glomeruli are illustrated. A single
lesion of segmental glomeruloscierosis affects one
glomerulus (airow). (Periodic acid Schiff, X 100.)
Fig. 2. B The lesion of segmental sclerosis is
discrete and located at the vascular pole.
(Periodic acid Schiff, X 250.)
the intrinsic problem of adequate glomerular sampling arises. The
diagnosis is particularly difficult in patients with subnephrotic
proteinuria, who comprise as many as 20% of cases in many adult
series [2, 5]. The biopsy-derived diagnosis of focal segmental
glomeruloscierosis is further complicated by the existence of a
variety of morphologic variants, and I will discuss the associated
prognostic and clinical correlates.
At our institution, interest in focal segmental glomerulosciero-
sis has been rekindled by our impression that the incidence of the
disease in the New York metropolitan population is steadily and
dramatically increasing. This perception prompted a systematic
review of 3963 native renal biopsies studied by the Columbia
University Nephropathology Laboratory over the 20-year period
from 1974 to 1993, among which 398 biopsy specimens with focal
segmental glomeruloscierosis were identified [6]. The incidence of
focal segmental glomeruloscierosis has progressively increased
from 2.5% in 1974 to 18.7% in 1993 and now constitutes our most
frequent diagnosis in native kidneys [6]. In spite of the emergence
of HIV-associated nephropathy in the mid-1980s, to our surprise,
a large portion of this increase in incidence was accounted for by
idiopathic focal segmental glomerulosclerosis in HIV-negative
patients. The reasons for this changing epidemiologic trend
deserve further study.
My purpose in this Nephrology Forum will be to explore the
heterogeneity of focal segmental glomerulosclerosis with respect
to its morphologic, pathogenetic, and clinical features, In the
course of this discussion, I will address the following questions:
Do the morphologic variants of focal segmental glomerulosciero-
sis have clinical relevance? How can primary and secondary focal
segmental glomerulosclerosis be distinguished? Is the distinction
between primary and secondary focal segmental glomerulosciero-
sis supported by experimental data? And how should the diversity
of focal sclerosis guide therapeutic decision-making?
The 2 patients presented here today illustrate two extremely
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Table 1. Focal segmeotal glomeruloscierosis
I. Idiopathic (primary) focal segmental glomeruloscierosis
II. HIV-associatcd nephropathy
III. Heroin oephropathy
IV. Secondary focal segmental glomerulosclerosis (adaptive
structural-functional response likely mediated by
glomerular hypertrophy/hyperliltration)
Reduced renal mass
Oligomeganephronia
Unilateral renal agenesis
Renal dysplasia
Reflux nephropathy
Sequelae to cortical necrosis
Surgical ablation
Any advanced renal disease with reduction in
functioning nephrons
Renal allograft
Initially normal renal mass
Diabetes mellitus
Hypertension
Obesity
Cyanotic congenital heart disease
Sickle cell disease
V. "Pattern" of focal segmental glomerulosclerosis due to renal
scarring
Focal proliferative glomerulonephritis (IgA
nephropathy, lupus nephritis, polyarteritis, etc)
Hereditary nephropathy
Diabetic nephropathy
Hypertensive arteriolonephrosclerosis
Membranous glomerulopathy
Eclampsia/pre-eclampsia
aModified with permission from Ref. 4.
different clinical and morphologic presentations of focal segmen-
tal glomerulosclerosis (FSGS). The first case is a "malignant,"
rapidly progressive form of idiopathic FSGS; the second is an
indolent, secondary form of FSGS related to glomerular "over-
work"; both can be considered extremes within the clinicopatho-
logic spectrum of the disease. Let us consider these and other
subtypes of FSGS in the context of a definition of classic idio-
pathic FSGS.
"Classic" FSGS
The morphologic features of idiopathic FSGS are well known to
all students of nephrology. For the purpose of this discussion, I
will refer to the following constellation of features as the classic
form of FSGS. The characteristic lesion, a discrete, segmental
solidification of the glomerular tuft, usually occurs in the perihilar
region in continuity with the vascular pole. In practice, however,
any segment of the glomerulus can be affected, especially as the
lesion evolves globally. In the affected areas, the glomerular
capillary lumina are segmentally obliterated by relatively acellular
matrix material, often associated with inframembranous hyalino-
sis, endocapillary foam cells, and Bowman's capsular adhesion.
Deposits of 1gM, C3, and, more variably, C1 are frequently found
in these areas. The overlying visceral epithelial cells often appear
swollen and can form a cellular "cap" over the sclerosed segment.
Important to the diagnosis of idiopathic FSGS is the relatively
normal appearance of non-sclerotic glomeruli, except for the
variable finding of visceral cell hypertrophy in these glomeruli.
Although foot-process fusion is always observed over glomerular
lobules that have undergone sclerosis in the course of diverse
pathogenetic insults, the distinguishing characteristic of idiopathic
Table 2. Morphologic variants of idiopathic focal segmental
glomerulosclerosis (FSGS)
Cellular variant
Collapsing variant
FSGS with diffuse mesangial hypercellularity
FSGS with tip lesion
FSOS with glomerulomegaly
FSGS is the presence of foot process fusion over nonsclerotic,
otherwise-normal-appearing lobules. Other ultrastructural alter-
ations of the podocytes common to many glomerular proteinuric
states are often observed, including visceral cell swelling, trans-
port vesicles, protein resorption droplets, and condensation of
cytoskeletal filaments. Podocyte detachment can occur in the most
severely damaged capillaries. In autopsy material and in biopsy
specimens in which it is possible to orient the tissue, the sclerosis
is often most pronounced in the juxtamedullary cortex, an obser-
vation first made by Rich nearly 4 decades ago [7]. This predilec-
tion is thought to be related to the larger glomerular volume and
reduced autoregulatory capacity of the juxtamedullary glomeruli.
In general, tubular atrophy and interstitial fibrosis occur in a
patchy distribution, proportional to the severity of the glomeru-
losclerosis. Often hyalinosis of the arterioles is present, with
continuity between the arteriolar intimal hyaline deposits and the
perihilar glomerular hyalinosis.
Although all of us are familiar with this classic portrait of FSGS,
in practice those of us who look at renal biopsies on a daily basis
recognize that this description hardly encompasses the diversity of
morphologic variants frequently encountered (Table 2).
Cellular variant. To the inexperienced observer, the cellular
variant of FSGS (Fig. 3) easily can be confused with a focal
proliferative glomerulonephritis. It is characterized by endocapil-
lary as well as extracapillary hypercellularity, usually in a focal
segmental distribution. Increased numbers of endocapillary cells
include endothelial cells, foam cells, and occasional infiltrating
neutrophils, and mononuclear leukocytes, at times associated with
karyorrhectic debris. In the extracapillary space, the swollen and
hyperplastic visceral epithelial cells form a "pseudocrescent"
without attachment to Bowman's capsule or continuity with the
parietal epithelium. Unlike a true crescent, these extracapillary
proliferations consist largely or entirely of poorly cohesive visceral
cells, often rich in protein resorption droplets, without the cell
spindling or pericellular matrix that characterizes true crescents of
parietal epithelial origin. In FSGS, a proliferative visceral epithe-
hal component is much more common than endocapillary prolif-
erative features. Using a definition of "cellular" that encompasses
both endocapillary as well as extracapillary hypercellularity,
Schwartz and Lewis identified this variant in 20 of 59 cases of
FSGS, the cellular lesions affecting from 5% to 44% of glomeruli
in a given case [8]. Applying a more restrictive definition of
cellular variant, that is, including only forms of FSGS with
predominantly endocapillary hypercellularity, we observed endo-
capillary proliferation as a dominant histologic feature in 11% of
286 cases of idiopathic FSGS [9]. Using antibodies to proliferation
cell nuclear antigen (PCNA, an auxiliary protein to the DNA
polymerase 3), and Ki-67 (MIB1, a non-histone protein associated
with the chromatid in G2 and M phase), we have demonstrated an
elevated proliferation index in both the endocapillary and the
extracapillary compartment of the glomerulus in idiopathic FSGS,
4 
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Fig. 3. Cellular variant of idiopathic focal
segmental glomeruloscierosis. There is segmental
endocapillary hypercellularity including
infiltrating leukocytes. (Hematoxylin-eosin,
x 400.)
with the highest endocapillary proliferation index in the cellular
variant [9]. We observed that patients with this biopsy picture
usually have an abrupt onset of fulminant nephrotic syndrome,
similar to that occurring in minimal-change disease. Schwartz and
Lewis observed that patients with the cellular form of FSGS are
more likely to have severe proteinuria and the nephrotic syn-
drome (14 of 20 patients) than are those without cellular lesions
(9 of 39 patients), and to have a shorter time course from clinical
onset of renal disease to biopsy [81. We also found a slightly higher
mean urinary protein level in "cellular" FSGS (8.2 g/24 hrs) than
in "classic" FSGS (5.6 gf24 hrs) [91, andwe observed evolution of
cellular features to a more classic sclerosing pattern on repeat
biopsy several years later. The same transition from initially
cellular to progressively more sclerosing lesions has been observed
in the natural history of recurrent focal sclerosis in the allograft
[10]. These findings support the concept that the cellular lesion is
an early morphologic event in the evolution of FSGS in some
patients (analogous to other forms of proliferative glomerulone-
phritis), particularly in patients with heavy proteinuria.
Collapsing variant. In 1986, Weiss et al described 6 black
patients with an unusual clinicopathologic complex of severe
nephrotic syndrome, rapid progression to renal failure, and
glomerular "collapse" [11], resembling the histologic lesion that
since has become recognized in HIV-associated nephropathy.
Two patients required dialysis within 10 weeks of clinical presen-
tation, and 5 had an ill-defined febrile illness. While it has been
argued that these patients actually might have had HIV-associ-
ated nephropathy, none were intravenous drug users, and only
one of the 6 subsequently developed AIDS. Recent data from the
University of North Carolina [121 and from our group [13] suggest
that this particularly "malignant," rapidly progressive form of
FSGS indeed represents a distinct clinicopathologic entity differ-
ent from HI V-associated nephropathy.
Patient 1 illustrates a typical instance of this entity. Clinically,
this variant of FSGS is characterized by severe nephrotic syn-
drome, often with massive proteinuria and rapidly progressive
renal failure, similar to the accelerated time course observed in
HIV-associated nephropathy. Morphologically several important
characteristics distinguish it from classic FSGS. First, the glomer-
ulus is often affected globally as well as segmentally in the early
stages. Rather than an expansion of the intracapillary region by
hyaline and matrix material, the endocapillary space is reduced by
implosive retraction (so-called "collapse") of the glomerular
capillaries without an identifiable increase in mesangial or intra-
capillary matrix material. On electron microscopic study, the
glomerular basement membranes typically are extensively wrin-
kled and folded. Unlike HIV-associated nephropathy, however,
this collapsing variant of idiopathic FSGS lacks endothelial tubu-
loreticular inclusions. The markedly swollen visceral epithelial
cells give the impression of hypercellularity, often filling the
urinary space and containing an abundance of protein resorption
droplets. The visceral epithelial proliferation index is highest in
this variant of FSGS and comparable to the levels reached in
HIV-associated nephropathy [14]. Important accompaniments to
the glomerular injury are striking tubular and interstitial disease,
which often appear out of proportion to the degree of glomerular
sclerosis, I will return to this point later, in the discussion of
pathogenesis. These tubulointerstitial changes, which quantita-
tively and qualitatively resemble those of HIV-associated ne-
phropathy, include interstitial fibrosis and inflammatory infiltra-
tion, tubular simplification, regenerative changes, atrophy, and
microcysts. Both groups of investigators who have studied this
variant of idiopathic FSGS have observed a black racial predom-
inance, as in HIV-associated nephropathy and heroin nephropa-
thy, but HIV infection and intravenous drug abuse have been
carefully excluded in their cohorts. Blacks comprised 81.3% [12]
and 61% [13] of cases respectively in the two series. Mean age at
diagnosis was 41.4 19.1 yrs (range, 19—81 years) [12] and 32.2
yrs (range, 1.5—72 years) [13}. When comparing their study
patients to idiopathic FSGS controls, both groups found that
patients with collapsing FSGS present with more severe findings
of proteinuria, hypoalbuminemia, and hypercholesterolemia, and
have a higher serum creatinine—3.5 versus 1.3 mg/dl [12] and 4.2
versus 2.0 [13]—despite a shorter time course from presentation
Fig. 4. Glomerular tip lesion. One lobule of the
glomerulus displaying endocapillary
hypercellularity and visceral cell hyperplasia
protrudes into the tubular pole (Periodic acid
Schiff, x 400.)
to biopsy (8.3 versus 48.7 months) [13]. Our group found a median
renal survival of 11.5 versus 50.5 months in controls with idio-
pathic FSGS [13]. None of 26 patients treated with steroids
responded, and only 1 of 6 treated with cytotoxic agents had a
partial remission of proteinuria [13]. Detwiler and coworkers
noted that 5 of 14 patients with collapsing FSGS reached dialysis
at 15 months, and 3 more died of complications of renal failure;
they found no such end-points among controls with idiopathic
FSGS [12]. The patients reported by Detwiler et al all were seen
between 1988 and 1990. In our retrospective analysis of FSGS
patients seen at Columbia-Presbyterian Medical Center over a
20-year period, we reviewed all slides to ensure that this entity had
not been missed because of a failure of recognition [6]. We were
intrigued to note that this collapsing form of P505 had not been
identified prior to 1979 yet has since steadily and dramatically
increased in incidence. It constituted only 3.6% of all idiopathic
FSGS from 1974 to 1983, but 18.5% from 1984 to 1993. These
data raise the specter of a possible environmental or infectious
factor, perhaps occurring in a genetically predisposed host. Given
its close morphologic resemblance to HIV-associated nephropa-
thy, a search for a possible viral etiology appears justified.
FSGS with diffuse mesangial hypercellularily. The presence of
mesangial hypercellularity has been accorded prognostic signifi-
cance in minimal-change disease. Reports in the early 1980s by
the International Study of Kidney Disease in Children [15] and
the Southwest Pediatric Nephrology Study Group [16] have
indicated a higher incidence of hematuria, hypertension, and
initial steroid resistance among pediatric patients with minimal-
change disease and diffuse mesangial hypercellularity, particularly
in the first year of followup. In the setting of P505, however, the
importance of mesangial hypercellularity is controversial. Sehoen-
eman and colleagues studied 13 pediatric patients with this
combination of histologic features; 10 of them developed renal
insufficiency, whereas none of the 11 patients who had P505
without mesangial hypercellularity did [17]. A higher rate of
progression to renal failure [18] and a higher rate of initial steroid
resistance [19] were described in early reports of P505 patients
with mesangial hypercellularity. However, a study of 57 patients
by Yoshikawa et al [20] and a study of 75 patients by the
Southwest Pediatric Nephrology Study Group [3] failed to confirm
these earlier findings. In the latter study, 29 of 75 children with
FSGS had mesangial hypercellularity, including 15 with mild, 10
with moderate, and 4 with severe hypercellularity. The only
correlation was a shorter time course from clinical presentation to
biopsy in the patients with mesangial hypercellularity. This obser-
vation suggested that mesangial hypercellularity might be a mor-
phologic feature of early disease. No correlation was found
between mesangial hypercellularity and outcome, and, although
patients with moderate to severe mesangial hypercellularity con-
stituted only 20% of the FSGS patients studied, 38% of those in
remission came from this subgroup. Thus, while diffuse mesangial
hypercellularity might be a feature of recent disease onset in
P505, the balance of evidence suggests that it does not adversely
affect outcome.
Glomerular "tip lesion." Tn 1984, Howie and Brewer coined the
term "glomerular tip lesion" to describe a distinctive lesion
occurring at the tubular pole, opposite the usual site of origin of
FSGS at the vascular pole (Fig. 4) [21]. The segment of the
glomerular tuft adjacent to the origin of the proximal tubule
displays sharply demarcated alterations that include aggregation
and marked vacuolization of podocytes, adhesion of the glomer-
ular basement membrane to the basal lamina of Bowman's
capsule, and swelling and foaminess of endocapillary cells, In
some cases, the involved segment actually prolapses into the
lumen of the S segment. The adjacent proximal tubular cells can
appear small and low lying, or alternatively, swollen and coarsely
vacuolated. As the lesion evolves, inframembranous hyalinosis
can develop, as can more typical segmental sclerosis extending to
the vascular pole, and progression to global sclerosis.
Although this lesion is morphologically distinct, its clinical
significance and relationship to classic P505 remain a source of
controversy. Howie and Brewer's original report suggested a
relatively good prognosis; all 13 patients treated with steroids
achieved a partial or complete remission of proteinuria, and only
1228 Nephrology Forum: Focal sclerosis
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one progressed to renal failure [21]. Morita et al [22] and Huppes
et al [23] have challenged the view that glomerular tip lesion
carries a benign prognosis by reporting a course and outcome
similar to classic FSGS. In fact, one of the patients reported by
Huppes et a! [23] progressed to end-stage renal disease and
developed recurrence of otherwise classic FSGS in the renal
transplant. In a followup study (mean 7.4 years) of 20 patients
with glomerular tip lesion, Beaman, Howie, and colleagues main-
tained the view that tip lesion is steroid responsive (10 of 18
steroid-treated patients achieved complete remission and 7 pa-
tients a partial remission of proteinuria), but described moderate
impairment of renal function in 50% of patients [241. Despite the
views of Beaman and colleagues to the contrary, these data
strongly suggest that the natural history of tip lesion differs from
that of minimal-change disease. Complicating the issue are obser-
vations that this morphologic lesion can occur superimposed on a
host of other glomerular diseases characterized by nephrotic-
range proteinuria, such as membranous glomerulopathy, mem-
branoproliferative glomerulonephritis, diabetic glomerulosciero-
sis, and IgA nephropathy [25]. Thus tip lesion might represent a
nonspecific response of the paratubular segment of the glomeru-
lar tuft to physical stresses imposed by high flow rates of protein-
rich filtrate coupled with the greater turbulence that probably
characterizes this bottleneck region of the urinary space.
The significance of the site of sclerosis within the three-
dimensional topography of the glomerular tuft has been much
debated. The predilection for lesions to occur at the vascular pole
might be related to this site's greater filtration pressures. Filtra-
tion pressure is greater at the afferent than at the efferent end of
the glomerular capillary bed because of the progressively increas-
ing intracapillary oncotic pressure in the efferent limb. After a
mean followup of 9.3 years, Morita and coworkers found no
difference in outcome between perihilar and peripheral FSGS,
whether diagnosed in an initial or repeat biopsy [22]. The finding
that subsequent biopsies often showed transition from paratubu-
lar to perihilar sclerosis suggested that the site of sclerosis vis-à-vis
the vascular pole has no prognostic significance. These data are at
variance with studies by Ito et a! [26] and Yoshikawa et a! [20] that
reported better preservation of renal function in patients with
exclusively peripheral sclerotic lesions. All these studies must be
tempered with the caveat that, short of serial sectioning of each
glomerulus using 3-dimensional morphometric analysis, it is im-
possible to estimate the number and extent of the segmental
lesions. Remuzzi et al demonstrated that, although the sclerotic
lesions of adriamycin-induced FSGS in the rat occupied, on
average, less than 3.5% of the capillary tuft volume, most glomer-
uli (>90%) were affected by segmental sclerosis, and that the
number affected was grossly underestimated by the counting of
abnormal glomeruli in conventional tissue sections [27]. Their
findings support the view that the segmental sclerosis in this
model is actually diffuse rather than focal in distribution. Because
such detailed morphometric studies are too laborious and time-
consuming to apply to routine renal biopsies, the relevance of
these findings to human disease is unknown.
Focal segmental glomeruloscierosis with glomerular hypertrophy.
Glomerular hypertrophy precedes the development of glomeru-
loscierosis in many experimental models. The most extensively
studied of these is /6 nephrectomy in rats [28]. Moreover,
unilateral nephrectomy, by imposing a hypertrophic stimulus on
the remnant kidney, can accelerate the development of glomeru-
loscierosis in a variety of experimental models of glomerulone-
phritis [29] as well as in experimental minimal-change disease
[30]. Renal hypertrophy also precedes the scierosing phase of
human and experimental diabetic glomeruloscierosis [31]. Ma-
neuvers that modify this hypertrophic response, including admin-
istration of a low-protein diet or angiotensin I-converting-enzyme
inhibitors, can markedly attenuate this hypertrophic stimulus and
reduce glomeruloscierosis in experimental animals [32, 33].
Innumerable studies have suggested that glomerular hypertro-
phy and sclerosis are linked pathophysiologically in these models,
but little data support the importance of this association in human
idiopathic focal segmental glomeruloscierosis. Certainly, while
glomerulomegaly is clearly important in secondary forms of focal
sclerosis, such as those related to obesity, reflux nephropathy,
cyanotic congenital heart disease, and oligomeganephronia, its
role in idiopathic focal sclerosis has not been adequately explored.
An important study in this regard was performed by Fogo and
coworkers, who demonstrated that glomerular hypertrophy in
pediatric patients with apparent minimal-change disease could
predict the subsequent development of FSGS [34]. Glomerular
area was on average 76% larger in the group that progressed to
FSGS compared with those whose subsequent course was benign.
Using a cut-off for glomerular area of 1.75 times that of age-
matched controls, the predictive value of glomerulomegaly for the
subsequent development of FSGS was 100%, but with a sensitivity
of only 40%. Studying a group of 40 adult patients with minimal-
change disease and 40 with FSGS, Jennette and colleagues
demonstrated a significantly greater mean glomerular volume in
the FSGS group compared with patients with minimal-change
disease and age-matched controls who died of trauma [35]. Some
patients with FSGS had glomerular volumes within the normal
range, however, so glomerulomegaly is not a prerequisite for the
development of idiopathic FSGS.
Secondary FSGS
We consider idiopathic FSGS a primary form of focal sclerosis
generally accompanied by overt nephrotic syndrome and morpho-
logic evidence of marked podocyte injury. Within the spectrum of
FSGS, HIV-associated nephropathy and heroin nephropathy are
more malignant forms having a clear etiologic association and
severe glomerular injury [36]. Correspondingly, these entities are
associated with a more rapid progression to renal failure, averag-
ing 2.5 years in heroin nephropathy and 2 to 4 months in
HIV-associated nephropathy, compared with the more indolent
mean time courses to uremia of 5 to 15 years for idiopathic FSGS
[1, 2, 5].
These forms of focal segmental glomeruloscierosis must be
distinguished from the secondary focal sclerosis that results from
structural-functional adaptations mediated by intrarena! vasodila-
tion and by increased glomerular capillary pressures and plasma
flow rates [reviewed in Ref. 4]. Such maladaptive glomerular
hemodynamic alterations can arise either through conditions that
cause a reduction in the number of functioning nephrons (that is,
unilateral renal agenesis, surgical ablation, oligomeganephronia,
or any advanced primary renal disease) or through mechanisms
that place hemodynamic stress on an initially normal nephron
population (as in morbid obesity with or without sleep apnea,
cyanotic congenital heart disease, and sickle cell anemia) (Table
2). These secondary forms of focal sclerosis are frequently misdi-
agnosed as primary focal segmental glomerulosclerosis because of
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excessive reliance on the specificity of the morphologic findings of
focal glomeruloscierosis at biopsy and failure to give adequate
weight to the complete clinical history. Misdiagnosis can lead to
inappropriate treatment with steroids or cytotoxic agents that
regularly proves ineffective. More often than not, these secondary
forms of focal segmental glomerulosclerosis are distinguished by
the absence of hypoalbuminemia, of edema, and of hypercholes-
terolemia in spite of nephrotic levels of proteinuria. Moreover,
nonsclerotic glomeruli are almost invariably hypertrophied. In
some of these secondary forms, such as refiux nephropathy, good
correlation exists between the maximum glomerular size and the
degree of renal functional impairment [37]. An important distin-
guishing feature is the ultrastructural finding of relatively mild,
segmental foot process fusion over the nonsclerosed segments,
with lesser degrees of visceral cell hypertrophy and hyperplasia. In
a systematic study of podocyte alterations in primary and second-
ary forms of FSGS, we noted that the mean percentage of the
glomerular surface area affected by foot process fusion was
significantly less in obesity (mean 42% 22%) and reflux
nephropathy (mean 25%) compared with classic FSGS (mean
65% 23%) [9]. The greatest degree of foot process effacement
was observed in collapsing (82% 24%) and cellular (87%
21%) forms of idiopathic FSGS, and these values were compara-
ble to those of HIV-associated nephropathy (mean 89% 17%)
and heroin nephropathy (73% 37%) [9], As the large standard
deviations suggest, although the mean percentage of foot process
fusion was higher in primary than in secondary FSGS, we found a
considerable degree of overlap. A good overall correlation (P <
.001) existed between the extent of foot process fusion and the
severity of proteinuria for all FSGS subgroups, such that the
distinction between primary and secondary FSGS was particularly
difficult in patients with subnephrotic levels of proteinuria. Al-
though helpful, the semi-quantitative assessment of foot process
fusion thus does not provide an absolute means for distinguishing
between these primary and secondary forms.
Patient 2 illustrates an obesity-related, secondary form of focal
segmental glomerulosclerosis with marked glomerular hypertro-
phy. In spite of nephrotic-range proteinuria, no hypoalbuminemia
was present and foot process fusion was minimal. In this condi-
tion, the percentage of glomeruli affected by glomerulosclerosis
usually is small and rarely, if ever, does the condition lead to renal
failure [38—40]. Jennette et al described the unusual case of a
patient with morbid obesity, sleep apnea, and a renal biopsy in
which 50% of the glomeruli were affected by segmental or global
sclerosis [39]. In an autopsy study of 22 patients with morbid
obesity, Verani described only one patient with end-stage renal
disease, the cause of which could not be determined [40]. Mor-
phologically, obesity-associated FSGS differs from idiopathic
FSGS in the invariable finding of glomerulomegaly, the infre-
quency of glomerular visceral epithelial hyperplasia, and no
predilection for the lesions to occur at the corticomedullary
junction [40]. The abundant lipid deposits and universal presence
of cardiomegaly in that study [40] suggested a possible role for
altered lipid metabolism and glomerular hyperfiltration in the
evolution of obesity-associated focal segmental glomeruloscierosis
[41]. Although hypoxia and polycythemia can also be contributory
factors, sleep apnea is not a constant clinical feature.
Nephrotic-range proteinuria without hypoalbuminemia typifies
many forms of secondary focal segmental glomerulosclerosis
likely mediated by hyperfiltration. The reason why hypoalbumin-
emia is frequently absent from these patients with heavy protein-
uria is unclear. Differences in hepatic protein synthesis and/or
tubular protein uptake and catabolism have been proposed.
Protein excretion underestimates total protein loss, as some or all
of the filtered protein can be reabsorbed by the proximal tubule.
Such differences in tubular reabsorptive load and protein handling
are supported by observations that there is significantly lower
fractional excretion of beta-2-microglobulin, less urinary N-acetyl-
beta glucosaminidase, and absence of glucosuria in patients who
have secondary FSGS without hypoalbuminemia compared with
nephrotic patients with hypoalbuminemia [42].
What is the critical point in humans at which a reduction in
functioning nephrons stimulates the adaptive mechanisms that
eventuate in progressive glomerulosclerosis? We can extrapolate
some information from long-term studies of living-related kidney
donors [43, 44]. In a study of 57 donors followed for a mean of
more than 23 years, neither a significant difference in serum
creatinine or creatinine clearance nor an increase in proteinuria
or hypertension compared with non-donor siblings was found [43].
In a longer term, 45-year followup study of 62 World War II
veterans who had undergone unilateral nephrectomy for trauma,
glomerular sclerosis and glomerular volumes were not signifi-
cantly increased in 10 subjects at autopsy, although kidney weight
was significantly higher [45]. The patients also had no increased
prevalence of hypertension. Of 28 living subjects, 5 had abnormal
renal function, 4 of whom had proteinuria greater than 250 mg;
conditions other than uninephrectomy could have accounted for
these differences, however. These data thus indicate that unine-
phrectomy in adulthood does not carry major adverse conse-
quences, even over prolonged periods. Curiously, FSGS does
appear to complicate unilateral renal agenesis, perhaps because of
the longer duration and more critical age of the insult. It is also
likely that the single kidney in this condition is not normal, but has
a reduced nephron number and more marked glomerular hyper-
trophy approaching levels seen in oligomeganephronia [46, 47].
Kiprov and colleagues described 8 patients with unilateral renal
agenesis in whom proteinuria was detected at ages 14 to 39 years,
with progression to end-stage renal failure in 6 [48]. Studies of
patients 10 years after undergoing partial nephrectomy of a
solitary kidney because of carcinoma have demonstrated that
patients with a greater than 75% overall reduction in renal mass
have the highest risk of developing FSGS [49]. Among 12 patients
undergoing partial nephrectomy of a single kidney, 9 developed
proteinuria, which was of moderate to high grade in 5 (0.9—6.7
g/day); 4 patients had documented FSGS on biopsy, and 2
progressed to renal failure,
Pathogenesis
Let us now turn to a consideration of the pathogenetic factors
in FSGS. I do not intend to discuss in detail the mechanisms of
secondary FSGS related to glomerular hypertension and hyper-
filtration; excellent reviews of these topics can be found elsewhere
[4]. Rather, I would like to discuss only some of the more recent
advances in our understanding of the cellular and molecular
events that underlie the disease.
Idiopathic FSGS
Toxic/immunologic factors. Although its cause is unknown,
primary (idiopathic) FSGS is likely to be a disease in which the
primary injury affects the visceral epithelial cell. The experimental
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models of puromycin- and adriamycin-induced FSGS have shown
that the earliest detectable morphologic abnormalities involve the
visceral cell, with effacement of foot processes, increased organel-
lar content, and local detachment from the glomerular basement
membrane [50, 51]. In-vitro studies by Fishman and Karnovsky
have demonstrated that puromycin is toxic to cultured visceral
epithelial cells [52]. On exposure to puromycin, these cells de-
velop blebbing and rounding up of their cell bodies, increased
surface microvilli, altered cell permeability, and reduced adhesion
to substrate. Cellular metabolism of proteins, sugars, and sialo-
proteins is altered, and membrane incorporation of glucosamine
and sulfate decreases. These in-vitro studies suggest derange-
ments in visceral cell metabolism that could alter the composition
and anionic charge of glomerular capillary wall components
synthesized by the visceral cell. Indeed, investigators have de-
scribed conflicting observations about the loss of heparan sulfate
proteoglycan within the glomerular basement membrane and the
reduction in the glycosylation of podocalyxin, the major mem-
brane-associated sialoglycoprotein of the visceral cell in this
model [53,
The nature of the putative visceral epithelial toxin in human
idiopathic FSGS remains elusive. Based on the likely relatedness
of minimal-change disease and focal segmental glomerulosciero-
sis, an immunologic basis for primary (idiopathic) FSGS has long
been suspected. More than 20 years ago, Shalhoub proposed that
minimal-change disease was a disorder of lymphocyte function
with increased levels of a lymphocyte-derived permeability factor
[55]. Such a factor remains to be isolated, yet work by several
investigators has come tantalizingly close. Koyama and coworkers
have produced T-cell hybridomas from the T-cells of patients with
minimal-change disease [56]. The hybridomas synthesize a gb-
merular permeability factor of 60,000—160,000 kD, which induces
proteinuria and foot process fusion in rats. This factor demon-
strated TNF-like activity in vitro, so it might be a lymphotoxin-
related substance, Similar putative permeability factors of varying
molecular weight have been isolated from serum, mononuclear
cells, lymphocytes, and urine of patients with minimal-change
disease [Reviewed in Ref. 57]. Along these lines, Savin, Sharma,
and colleagues have recently described a permeability factor of
100—120 kD in the serum or plasma of approximately 30% of
patients with FSGS and adult steroid-resistant nephrotic syn-
drome [58, 59]. This protein is not strongly cationic, and thus is
unlikely to act by neutralization of fixed negative charges in the
glomerular capillary wall [59]. Moreover, it is distinct from
albumin, immunoglobulin, or any known lymphokine. These
investigators have devised a method for predicting the recurrence
of FSGS in the allograft using a bioassay that measures the
volumetric response to oncotic pressure gradients in isolated rat
gbomeruli [60]. That increased glomerular permeability could be
identified within several minutes of exposure to this serum factor
suggested a cellular response. As yet, this permeability factor has
not been identified in patients with HIV-associated nephropathy
(Savin V, personal communication), but more studies will be
needed to determine the subset of FSGS patients in whom this
factor might be operative. Its presence underlies the rationale for
plasmapheresis in the treatment of recurrent FSGS in the al-
lograft [61, 62]. Recurrent FSGS occurs in 20% to 50% of
allografts and favors younger age groups and patients whose
original disease progressed rapidly to renal failure [63, 64]. It
provides an ideal natural model for studying the disease, because
its precise onset and evolution can be closely monitored. A better
understanding of the nature and source of this factor and how it
works at the cellular level perhaps will explain why some patients
with primary FSGS respond so dramatically to steroids while
others do not. Conceivably this factor might be toxic to visceral
epithelial cells, possibly acting through disruption of cell adhesion
to the basement membrane or alteration of basement membrane
components synthesized and maintained by the visceral epithelial
cells.
Recently, Dantal and coworkers have achieved reductions in
proteinuria in transplant patients with recurrent FSGS by remov-
ing plasma proteins through adsorption onto staphylococcal pro-
tein A [65]. When the adsorbed proteins were eluted and injected
into rats, a three- to fivefold increase in urinary albumin excretion
resulted. Because the active fraction of the eluate had a molecular
weight below 100,000 kD, the factor involved probably was not
intact immunoglobulin. The biochemical nature of this plasma
protein and its relationship to the serum factor described by Savin
remain to be elucidated.
Genetic and racial factors. It has long been appreciated that
black race is a risk factor for the more malignant forms of FSGS,
including heroin nephropathy, HIV-associated nephropathy and,
most recently, the collapsing variant of idiopathic FSGS. HIV-
infected whites are more likely to develop immune-complex-
related glomerular disease, whereas HIV-infected blacks are at
greater risk for the development of FSGS [66—68]. This strong
black racial predominance persists even if intravenous drug
abusers are excluded from consideration [57]. Not only is HIV-
associated nephropathy more common in blacks, it also is more
severe in blacks; whites have a higher incidence of the more
benign, mesangial-proliferative forms [57]. These racial differ-
ences also might extend to idiopathic FSGS. One New York
center reported that a higher percentage of black and Hispanic
children with idiopathic nephrotic syndrome have FSGS (32%)
compared with whites (20%) [69]. Black and Hispanic children
with FSGS have a higher serum creatinine level at presentation
than do their white counterparts, and 50% will reach end-stage
renal disease by 3 years; by contrast, actuarial analysis of predom-
inantly white pediatric patients with FSGS yields 50% kidney
survivals of 10 to 17 years [69]. From 1987 to 1989, black and
Hispanic children accounted for 23% of all pediatric renal trans-
plants performed (data from the North American Pediatric
Registry) but for 38% of all transplants performed for FSGS. In
South Africa, FSGS appears to be the most common lesion in
black patients with idiopathic nephrotic syndrome [70].
What accounts for this strong black racial predilection to
FSGS? An increased frequency of certain HLA hapbotypes among
patients with idiopathic FSGS and heroin nephropathy has been
reported [71, 721. Such genetic analyses have yet to be performed
in HIV-associated nephropathy. Could this increased propensity
for FSGS relate to the inherently larger gbomerular volume in
blacks than whites, or are there genetically controlled differences
in the propensity for extracellular matrix production, analogous to
keboid formation in the course of wound healing? Blacks have
been shown to have larger glomerular volumes than whites in the
absence of obvious renal disease [73]. In further studies using
renal specimens obtained from trauma victims, the same group
has found the mean glomerular volume to be 3.12 .12 X 106
im3 in African-Americans and 2.43 .14 >< 1O tm3 in age-
matched Caucasians from 17 to 60 years of age (mean 31 years),
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although there was no difference in kidney weight, body mass or
heart weight (Striker L, personal communication). Recent work
by Merlct-Benichou might shed light on this racial difference in
glomerular volume [74, 75]. She has found reduced numbers of
glomeruli and larger glomerular volumes in newborn rats exposed
to toxins in utero [75] and in infants born with small placentas and
low birth weights [741; these observations suggest that socioeco-
nomic differences, such as poor nutrition or exposure to toxins
during gestation, might affect the developing kidney and result in
a reduced glomerular population with larger glomerular volume.
Glomerulomegaly could be an important predisposing factor to
glomerulosclerosis [76, 771; in fact, this possibility was proposed as
a risk factor in the development of diabetic nephropathy among
Pima Indians, whose glomeruli are even larger than those of
African-Americans [73].
Seconda,y FSGS
Hemodynamic factors. In secondary FSGS, damage to the
glomerular capillary wall is not a primary event, but results
secondarily from adaptive mechanisms that follow glomerular
overwork, either due to reduced numbers of functioning nephrons
or to increased functional stress on an initially normal nephron
population. A vast literature supports the idea that subtotal
nephrectomy in the rat leads to functional hypertrophy of rem-
nant nephrons. Within 2 to 3 weeks of ablation, whole-kidney
GFR and kidney weights increase. The magnitude of these
alterations correlates with the amount of renal mass excised. In
this experimental setting, both the afferent and efferent arteriolar
resistances are decreased. However, there is a disproportionately
greater reduction in afferent arteriolar resistance, which leads to
increased glomerular capillary plasma flow rate and glomerular
capillary hydraulic pressure. These functional adaptations even-
tually become maladaptive in that they lead to structural damage
to the glomerular endothelial, mesangial, and visceral cell com-
ponents. The morphologic manifestations of this injury include
glomerular capillary microthrombosis; microaneuiysms; mesang-
ial enlargement, proliferation and sclerosis, inframembranous
hyalinosis; and visceral cell detachment [4, 78, 79].
Hypertrophic-growthlfactors. Initially it was thought that these
glomerular structural alterations could be explained entirely by
the damaging effects of high glomerular capillary flow rate and
hydraulic pressure. Recent work by Ichikawa, Fogo, and Yoshida
has demonstrated the inadequacy of this theory, however [80—83].
Using serial micropuncture studies of individual glomeruli, they
made the important observation that glomerular capillary hydrau-
lic pressure and sclerosis in individual glomeruli were dissociated
in the models of puromycin aminonucleoside nephrosis in unilat-
erally nephrectomized Munich-Wistar rats and in adriamycin
nephropathy [82]. But they also noted a strong association be-
tween glomerular hypertrophy and subsequent sclerosis. In stud-
ies comparing the effects of subtotal nephrectomy with ureteral
diversion, glomerular capillary hydraulic pressure and single-
nephron glomenilar filtration rate were elevated in both models
[81]. Marked hypertrophy and glomeruloscierosis were present
only in the rats with subtotal nephrectomy, however. Moreover,
ACE inhibitors administered in the early stages were effective in
attenuating the sclerosis without altering glomerular capillary
hydraulic pressure in some models [82]. In the % nephrectomy
model, when the maximum planar area and degree of glomerular
sclerosis were quantitated, a positive correlation existed between
hypertrophy and sclerosis in the early stages of sclerosis and a
negative correlation in the later stages, giving a biphasic curve
[83]. These data provide strong evidence that hypertrophy and
sclerosis are pathophysiologically linked. This association is con-
sistent with the observation that young rats, in which relative
hypertrophy of the juxtamedullary glomeruli is a normal develop-
mental phenomenon, are at greater risk for the development of
glomerulosclerosis than older rats, in which glomerular size is less
disparate [84]. The means by which glomerular hypertrophy
predisposes the glomerular capillary wall to injury might relate to
mechanical injury mediated by greater glomerular capillary lumi-
nal diameters, because wall tension is a direct function of trans-
mural pressure and capillary luminal diameter [85], as predicted
by the Laplace relationship. Alternatively, glomerular hypertro-
phy could promote glomerular injury through cellular events
mediated by disruption of the glomerular podocytes, which are
inadequate to cover the enlarged glomerular tuft [78], resulting in
cell body attenuation, thinning of primary processes, and simpli-
fication of foot processes. The degree to which glomerular
hypertrophy is accompanied by increased glomerular cell prolif-
eration (that is, hyperplasia) or cell volume is a critical issue that
has not been adequately explored [76]. Experimental studies by
Fries et al on a toxic form of visceral cell disease with superim-
posed nephrectomy have indicated an inability of rat podocytes to
proliferate in response to hypertrophic stimuli [86]. However,
conflicting data in rats [78] and humans [9, 14] suggest that
visceral cells are indeed able to enter S phase and undergo
mitosis.
In ablation models, numerous possible growth factors have
been implicated in the development of glomerular hypertrophy.
These factors could be derived from platelets, infiltrating mono-
nuclear cells, or resident mesangial cells. Recent evidence points
to an important role for angiotensin II as a growth factor
independent of its hemodynamic effects. Angiotensin II promotes
the growth of smooth muscle cells of the vasculature, heart, and
kidneys [87]. In vitro it induces hypertrophy but not proliferation
of cultured adult rodent mesangial cells [88], and it induces
proliferation and increased type-IV collagen production by fetal
mesangial cells or immortalized adult mesangial cells [89]. Noble
et a! reported that angiotensin II causes a dose-dependent
increase in mRNA for TGF-3 as well as fibronectin, biglycan, and
collagen type-I in cultured mesangial cells; this effect could be
blocked by antibody to TGF-13, consistent with an autocrine effect
[90]. These findings suggest a novel mechanism whereby glomer-
ulosclerosis might occur in secondary forms of FSGS in which
angiotensin II is upregulated. Moreover, they provide insight into
the earlier observations by Ichikawa and Fogo that glomeruloscie-
rosis can progress in the absence of glomerular capillary hyper-
tension, and suggest that angiotensin II exerts effects independent
of its hemodynamic action [91].
Could TGF-/3 be the final common pathway to glomerular
extracellular matrix production in many or all the forms of FSGS
we have discussed today? TGF-3 is a cytokine that acts at three
levels to (1) stimulate matrix synthesis of fibronectin, proteogly-
cans, and collagen, (2) inhibit matrix degradation, and (3) increase
cell adhesion to matrix proteins via modulation of integrins,
particularly the alpha S 3-i fibronectin receptor [reviewed in Ref.
92]. Yoshioka has demonstrated TGF-j3 protein in the mesangium
and peripheral glomerular basement membrane of human renal
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biopsy specimens with idiopathic focal segmental glomeruloscie-
rosis [93]. TGF-f31 mRNA expression was identified primarily in
indigenous mesangial cells and to a lesser extent in infiltrating
monocytes-macrophages. Normal glomeruli and glomeruli from
patients with minimal-change disease showed either no TGF-/3 or
only negligible levels [93]. Just as human FSGS might have an
early cellular phase, glomerular cellular proliferation detected by
PCNA immunostaining precedes the development of glomerulo-
sclerosis in the % nephrectomy model in the rat [94]. This
response is characterized by mesangial cell proliferation (associ-
ated with increased glomerular PDGF expression) and by the
influx of macrophages and platelets, all of which may be sources
of TGF-f3. It is interesting that, in this model, immunostaining for
type-I collagen could be localized to the cytoplasm of podocytes,
as well as mesangial areas. Perhaps the visceral epithelium
contributes to sclerosis in this model.
Viral factors. Clues to the molecular events that underlie the
development of FSGS have come from recent advances in our
understanding of HIV-associated nephropathy. Data concerning
the possibility of direct viral infection of the renal parenchyma
conflict. Using the relatively insensitive technique of in-situ hy-
bridization, viral DNA was detected in glomerular epithelial and
tubular cells by Cohen et al [95] but not by Pardo and colleagues
[96]. Alpers et al used in-vitro cell culture systems but were unable
to infect human mesangial cells with several lymphocyte-tropic
and macrophage-tropic strains of HIV-1 [97]. By contrast, Green
and colleagues successfully infected human glomerular endothe-
hal cells and, to a lesser extent, mesangial cells, but not visceral
epithelial cells, with several laboratory and clinical strains of
HIV-1 [98]. But because these studies used pretreatment with
DEAE-dextran, possibly obviating receptor-mediated viral inter-
actions, this result actually might represent a model of transfec-
tion rather than infection. Putative glomerular receptors for
HIV-1 include mesangial FcR and CD4 [99]. Using microdissec-
tion polymerase chain reaction (PCR) studies in human renal
biopsies, Kimmel and colleagues demonstrated HIV genome in
glomerular cells, tubular cells, and infiltrating inflammatory cells,
but not in interstitial cells, from biopsy tissue with HI V-associated
nephropathy [100]. However, HIV-positive patients without renal
disease and with other forms of renal disease such as immune-
deposit glomerulonephritis had similar, positive polymerase chain
reaction results. Although these data suggest that HIV virus can
infect renal parenchymal cells, transcription of HIV-1 RNA has
not yet been demonstrated in renal cells in vivo. Infection of renal
tissue per se, however, does not appear to be sufficient to cause
HI V-associated nephropathy; other mechanisms likely are neces-
sary.
Insights into what such a molecular "trigger" might be have
been provided by studies using transgenic mice. The first trans-
genie model of HIV-associated nephropathy was produced by
researchers at the National Institutes of Health, who used a
noninfectious HIV provirus containing an inframe deletion of gag
and pol sequences, which encode for structural core proteins and
enzymes of HIV-i, respectively [101, 102]. These transgenic mice
develop renal disease characterized by proteinuria, focal segmen-
tal glomerulosclerosis, interstitial nephritis, and tubular micro-
cysts; their illness closely mimics human nephropathy. Another
recent transgenic model, containing a deletion of envelope (env)
in addition to gag and pol, also has developed nephropathy [103].
These findings suggest that intact, infectious virus is not necessary
to produce nephropathy. Nephropathy might be conferred by any
or all of the HIV-1 regulatory proteins, which include tat (a
transcriptional initiation factor), rev (which regulates viral RNA
splicing), vpu (which regulates viral budding), and vif and vpr
(both virulence factors). Viral proteins themselves might be toxic
to visceral epithelial or tubular cells or might induce renal cells to
release cytokines that initiate FSGS. In this regard, both TGF-13
and FGF are induced in transgenic and human HIV-associated
nephropathy [104—107]. Intriguing is the possibility that tat pro-
tein stimulates transcription of host fibrogenic cytokines such as
TGF-J3 by indigenous renal cells or infiltrating monocytes. Such a
mechanism, already demonstrated in human macrophages, has
been linked to HIV-induced hematopoietic suppression [108]. Tat
protein is a particularly good candidate, because its genetic
sequence is preserved in the transgenic models of HIV nephrop-
athy produced thus far and because it is actively released by
infected cells and can be taken up by various cell types, with
resulting inhibitory or stimulatoiy effects on cell proliferation. It
seems possible that tat protein could transactivate TGF-f3 by renal
cells, in a role analogous to that of the tax gene product in human
T-lymphotropic virus type-i [109]. Tat protein interacts with
particular sequences in the long terminal repeat (LTR) to in-
crease transcription rate and elongation of mRNA transcripts and
also, through interaction with TAR (tat activation response),
might loop back to bind promoter regions in the host genome.
Studies of TGF-/3 immune regulation in the simian immunodefi-
ciency virus (SIV) model and the newly described feline immu-
nodeficiency (FIV) model of HIV nephropathy may provide an
in-vivo system for exploring these interactions [110, iii]. Other
viruses not yet identified might play a similar pathogenetic role in
forms of idiopathic FSGS.
Tubulointerstitial injury. I now would like to briefly consider the
factors that might mediate tubulointerstitial disease in FSGS,
because this area has received insufficient attention. Particularly
in the rapidly progressive forms of FSGS, such as HI V-associated
nephropathy and the collapsing variant, tubulointerstitial injury
often is disproportionately severe relative to the degree of gb-
merulosclerosis and cannot be accounted for merely on the basis
of gbomerular "drop-out" with atrophy of the dependent tubular
system. In fact, in more aggressive forms of FSGS, tubular
simplification and regenerative changes, interstitial inflammation,
fibrosis, and edema can be diffuse changes in the presence of the
more focal glomerular lesions. Evidence supports the concept that
glomerular proteinuria itself can mediate tubular injury, intersti-
tial inflammation, and fibrosis [112—115]. Tubular epithehium can
be injured by the high rate of protein resorption and lysosomal
degradation [112, 113]. Albumin-overloaded rats develop intense
renal interstitial monocytic infiltrates and increased cortical ex-
pression of TGF-/3i mRNA followed over several weeks by the
development of interstitial fibrosis [116]. Kees-Folts and Schrei-
ner have demonstrated a urinary lipid fraction that is chemotactic
for macrophages in this model [115]. These findings suggest that
proximal tubular cells can generate chemotactins through the
catabolism of lipid-rich albumin. In puromycin aminonucleoside
nephrosis, the severity of interstitial fibrosis correlates closely with
the level of proteinuria and is preceded by interstitial monocyte
infiltration [117]. Another recently identified substance that might
promote interstitial monocyte recruitment and lead to progressive
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tubulointerstitial injury in the setting of chronic glomerular pro-
teinuria is osteopontin. This anti-crystalluric substance, synthe-
sized at many levels of the tubule, is upregulated in experimental
glomerular disease, and acts as a chemotactic adhesive factor for
vascular smooth muscle cells, endothelial cells, and macrophages.
Its importance recently was demonstrated in the thy-i model,
aminonucleoside nephrosis, and passive Heymann nephritis,
[118], as well as overload proteinuria (Eddy A, personal commu-
nication), although its role in human FSGS remains to be
explored. In these models, tubular epithelial cells expressed
increased levels of osteopontin mRNA and protein which pre-
ceded the infiltration of monocytes-macrophages. It has been
postulated that cytokines and growth factors released by the
glomerulus in the course of glomcrular injury induce osteopontin
expression [118], eventuating in tubulo-interstitial injury.
Treatment
Distinguishing between primary and secondary FSGS has major
therapeutic implications. Proteinuria can be caused by a variety of
alterations in the cellular and matrix components of the glomer-
ular capillary wall, The severity of proteinuria can be modulated
by hemodynamic factors that govern the force with which proteins
are driven across the glomerular filtration barrier. If we assume
that idiopathic FSGS is a primary disease of the glomerular
capillary wall, possibly at the level of the visceral epithelium, and
that secondary FSGS results from a variety of conditions that
promote glomerular capillary hypertension and increased trans-
capillary flow rates, it stands to reason that these two entities
require very different therapeutic approaches.
Preliminary clinical and experimental studies suggest that pa-
tients with secondary FSGS can benefit from antihypertensive
therapy, particularly the use of ACE inhibitors, and from dietary
protein restriction [119]. Studying a cohort of 19 such patients
including cases of healed crescentic glomerulonephritis, reflux
nephropathy, scarred IgA nephropathy, unilateral renal agenesis,
and obesity, Praga and coworkers documented a beneficial anti-
proteinuric effect of captopril, probably because of its selective
vasodilation of the efferent arteriole, a process that leads to
reduction in glomerular capillary hydrostatic pressure [42]. A 50%
reduction in proteinuria following ACE inhibition was achieved in
patients with secondary FSGS in whom there was heavy protein-
uria (7—8 g) but normal serum albumin, but ACE inhibition
produced little or no effect in hypoalbuminemic patients with
membranous glomerulopathy and comparable proteinuria [41]. In
patients with secondary FSGS, ACE inhibition and nonsteroidal
antiinflammatory agents possibly exert an additive effect by syn-
chronous after-load and pre-load reduction in glomerular pres-
sure through postglomerular vasodilation by the ACE inhibitor
and preglomerular vasoconstriction by the NSAID [120].
The treatment of primary (idiopathic) FSGS is extremely
controversial [121—127]. Opposing views for and against treatment
stem in part from a lack of randomized, controlled trials and in
part from the heterogeneous natural history of untreated primary
focal segmental glomerulosclerosis. This variability is reflected in
the fact that some patients can have relatively mild, subnephrotic
proteinuria with a very indolent course and stable renal function,
while others have severe nephrotic syndrome with progressive
renal failure. Among the factors that might predict progression
are initial steroid resistance [127], more severe proteinuria [120],
and a higher serum creatinine level at presentation. Among
pathologic features, one study found interstitial fibrosis to be the
only significant histologic variable [124]. Earlier studies suggested
that FSGS was predominantly a steroid-resistant lesion with less
than a 30% response and a high relapse rate following discontin-
uation of therapy. In a more recent study from Toronto, 44% of
children and 39% of adults presenting with similar clinical param-
eters responded to steroid therapy [122]. However, only 33% of
adults were offered treatment. The dismal outcome in adults
therefore might relate in part to undertreatment.
The role of alternate immunosuppressive agents remains to be
defined. An Italian collaborative study noted up to 60% complete
remission of nephrotic syndrome in adults receiving prolonged
corticosteroid therapy (median 6 months) or combinations of
low-dose steroids and azathioprine or cyclophosphamide [124].
Cyclosporine has been effective in some steroid-resistant ne-
phrotic patients, although proteinuria frequently recurs on dis-
continuation of therapy, especially if treatment is withdrawn too
abruptly [125]. Because agents such as ACE inhibitors, which
modulate glomerular capillary hemodynamics, can reduce the
driving force for proteinuria, these agents also can have a
beneficial effect in achieving a reduction in proteinuria in some
patients with idiopathic P505, without necessarily correcting the
primary defect in glomerular capillary wall permselectivity.
Though data in humans are lacking, by reducing levels of protein-
uria, ACE inhibitors also might protect against the development
of progressive tubulointerstitial disease, No therapy has been
shown to be effective in heroin nephropathy or HIV nephropathy,
although preliminary reports suggest that AZT slows the progres-
sion to renal failure in the latter [128].
In summary, although FSGS is a common pattern of renal
injury, its morphologic and etiologic expressions are diverse.
Hemodynamic, genetic, immunologic, toxic, and viral factors all
might play a pathogenetic role (Fig. 5). The final common
pathway of glomerulosclerosis, and tubulo-interstitial disease
however, might involve convergent molecular mechanisms even-
tuating in extracellular matrix production. A better understanding
of the specific pathogenetic mediators of these various subtypes of
FSGS will allow the future design of better and more specific
preventive and therapeutic strategies.
Questions and answers
DR. EDwARD P. NORD (Division of Nephrology, State University
of New York at Stony Broolç Stony Broolç New York): Is there an
adequate animal model for testing the relative importance of the
hemodynamic versus non-hemodynamic factors involved in the
pathophysiology of focal sclerosis?
DR. D'AGATI: Animal models of FSGS fall into two major
categories: experimental models that produce toxic injury to the
visceral epithelium, such as puromycin aminonucleoside and
adriamycin nephrosis, and ablation models. Toxic models likely
interfere with critical biochemical cellular processes required to
maintain the complex cytoskeletal structure of the podocytic
extensions and their attachment to the outer glomerular basement
membrane. In renal ablation models, visceral cell injury also
occurs and results in simplification of the podocyte and focal
detachments from the glomerular basement membrane. Kriz has
termed this phenomenon "podocyte insufficiency" [78], because
the visceral cells appear to lack the ability to proliferate in
response to the expanded surface area of the glomerular tuft. In
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both types of models, the level of proteinuria correlates with the
degree of visceral cell detachment.
To directly answer your question, one can accentuate the
proteinuria seen in toxic models by superimposition of a hemo-
dynamic stimulus such as unilateral nephrectomy [86, 129, 130].
Conversely, Fogo, Tanaka, and colleagues have shown that treat-
ment with ACE inhibitors in the first 4 weeks of puromycin
aminonucleoside nephrosis mardedly attenuates the proteinuria
[77, 131]. Interestingly, a similar reduction in proteinuria could
not be achieved by early administration of an angiotensin II
receptor antagonist, a discrepancy that likely is due to ACE-
inhibitor-mediated activation of bradykinin [132], which causes
dilation of the efferent arteriole and a fall in glomerular capillary
hydrostatic pressures. Even more intriguing was their observation
that, although early treatment with an ACE inhibitor reduced
glomerular proteinuria in puromycin nephrosis, it had no effect on
the subsequent development of glomerulosclerosis [131, 132].
However, delayed therapy with an ACE-inhibitor or angiotensin
Il-receptor antagonist at 16 to 28 weeks had an equally beneficial
effect in reducing glomeruloscierosis. Thus in these models, the
early-phase proteinuria is independent of angiotensin II but the
subsequent progression to glomeruloscierosis is dependent on
mechanisms involving angiotensin II.
The applicability of these experimental observations to human
idiopathic FSGS remains unproven. I think exciting avenues of
future investigation will involve isolation of the human "perme-
ability factors" described by Savin [58] and Dantal [65] and
production of a "toxic" model of glomerular proteinuria by their
administration to experimental animals. Subsequent modulation
of hemodynamic factors then could be explored in an experimen-
tal model that more closely approximates the human disease.
Clearly, however, hemodynamic mechanisms alone are insuffi-
cient to explain the pathogenesis of idiopathic FSGS.
DR. FREDERICK MILLER (Chairman, Department of Pathology,
State University of New York at Stony Brook): You provided us with
a rather complicated classification scheme for the idiopathic
forms of focal sclerosis. As far as I know, neither this nor any
other classification scheme is universally accepted among nephro-
pathologists or, indeed, among nephrologists. To some extent, I
think it's a question of whether one's a "splitter" or a "lumper."
Given that therapy doesn't yet have much to offer patients with
any form of idiopathic segmental sclerosis, I wonder whether the
different designations are really useful.
DR. D'AGATI: The morphologic schema for idiopathic FSGS
that I have proposed is simply a working classification that I find
useful in sorting out the different morphologic expressions of
FSGS. Although it might appear unnecessarily detailed, I believe
that it provides useful guidelines to the renal biopsy interpretation
of this complicated disease entity and underscores the surprisingly
broad histologic diversity of the disease.
Most important, it is apparent from this classification that not
all histopathologic expressions of FSGS are alike. Particularly in
the instance of the "collapsing" variant of idiopathic FSGS, this
classification allows the identification of a subset of patients at
higher risk for treatment failure and progression to renal failure.
From a practical standpoint, it also is important that we recognize
the existence of the "cellular" variant, because an inexperienced
pathologist could easily confuse it with proliferative glomerulone-
phritis. In my opinion, evidence favors the view that the glomer-
ular tip lesion and diffuse mesangial hypercellularity in the setting
of FSGS are likely histologic findings without prognostic import.
In short, I approach this schema as a working classification, the
validity of which will only be borne out by future studies into the
pathogenesis of FSGS.
DR. JORDAN J. COHEN (Dean, School of Medicine, State Univer-
sity of New York at Stony Brook): Does the collapsing form of focal
sclerosis tend to recur in patients who receive a transplanted
kidney?
DR. D'AGATI: None of the patients in our series received a renal
transplant, so I am unable to address your question specifically.
However, I have seen one patient who developed a collapsing
form of FSGS in the allograft 2 weeks following transplantation.
It is interesting that 2 previous biopsies of her native kidneys had
shown a more classical pattern of FSGS, without collapsing
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features. Dr. J. Charles Jennette has told me that he has seen
collapsing FSGS in an allograft apparently as a de-novo occur-
rence.
DR. MARTJN LIEBowITz (Division of General Medicine, State
University of New York at Stony Brook): In the first case presented,
I was struck by the fact that, at a time when the creatinine
clearance had fallen to 5 cc/mm, the urinary protein excretion was
36 g/day. I don't think I've ever seen a discrepancy that great. It
points to greatly increased glomerular permeability. Is that your
conclusion as well?
DR. D'AOATI: I agree that the proteinuria is surprisingly severe
for the level of renal functional impairment and points to a
profound defect in glomerular permselectivity. As I pointed out in
my talk, the collapsing variant of idiopathic FSGS characteristi-
cally displays a higher mean urinary protein excretion than do
idiopathic FSGS controls [12, 131; the increased protein excretion
suggests a severe increase in glomerular permeability. A contrib-
utoiy factor in the first patient likely was the severe tubulo-
interstitial injury, which probably impaired tubular protein reab-
sorptive capacity, thereby compounding the urinary losses.
DR. PIERCE GARDNER (Division of Infectious Diseases, State
University of New York at Stony Brook): I was intrigued by your
epidemiologic observations that the incidence of focal sclerosis
apparently began to increase in around 1979, which is approxi-
mately the onset of the AIDS era. This observation raises the issue
of a retrovirus as a possible cause. Do we have detailed epidemi-
ologic descriptions of these cases? Do we know about sexual
partners? Have the parents of the children with idiopathic focal
sclerosis been looked at? Do we know the results of T-eell
studies?
DR. D'AGATI: No. Such epidemiologic questions have not yet
been addressed in any systematic way. I can tell you, however, that
our series of patients with collapsing idiopathic FSGS had no
overt signs of viral infection. Constitutional symptoms were
absent, and white cell counts were unremarkable. However,
Detwiler and colleagues have described a minority of patients with
subjective fever, diarrhea, arthralgias and myalgias, and rash
among 16 patients with idiopathic collapsing FSGS [121. But no
specific viral cause has yet been identified.
DR. GARDNER: Have any secondary cases of collapsing FSGS
been reported?
DR. D'AOATI: No, so we think that this is a form of primary
FSGS that is particularly malignant in its course. A similar
histopathologic pattern can be seen in HIV-associated nephrop-
athy. The cases that we and the North Carolina group have
described, however, occurred as "idiopathic" forms in HIV-
negative patients who had no history of intravenous drug abuse.
Because of the recognition of collapsing FSGS in the 1980s and its
morphologic resemblance to HIV-associated nephropathy, we
plan to investigate a possible viral etiology. I think it quite likely
that viral causes exist for idiopathic FSGS that remain to be
identified.
DR. CoI-mN: How certain are you that the incidence of focal
sclerosis is actually increasing? As I understood the evidence you
presented, the percentage of the biopsies processed by your
laboratory that yielded a diagnosis of focal sclerosis has increased
over the past decade. Are we certain that the criteria used to
diagnose focal sclerosis did not change during that period?
Likewise, are we certain that the indications for biopsy, and hence
the denominator of the statistic, did not change?
DR. D'AGATI: Your question is well taken. The incidence that I
have described is a renal biopsy incidence of idiopathic FSGS
determined from retrospective analysis of all consecutive renal
biopsies accessioned by our nephropathology laboratory over the
past 20 years. The patient population served by our institution has
not changed substantially over that time period. Moreover, I don't
believe that the indications for renal biopsy in our institution have
changed for adults or children. Thus, we believe that our increas-
ing biopsy incidence of idiopathic FSGS reflects a true increase in
disease incidence. It may take several years before this is reflected
in the transplantation registries as an enlarged population of
ESRD patients with FSGS as their original disease. Dr. Amir
Tejani has told me, however, that the North American Pediatric
Transplant Registry already is observing such a trend.
DR. MILLER: We have been looking at renal biopsies in our
geographic region for more than 20 years and have been working
with a comparable set of nephrologists who are presumably
applying the same criteria as your group when performing biop-
sies. We have had the same experience that you have had. The
number of cases of focal segmental glomerular sclerosis has
increased substantially, and the collapsing variant has become
more frequent.
DR. D'AGAlI: I am delighted to learn that this observation is
not limited to our own medical center but might be a more
generalized phenomenon. I am unaware whether similar trends
are being observed throughout this country or in other parts of the
world.
DR. THOMAS MANI5 (Division of Nephrology, Nassau County
Medical Center, East Meadow, New York): As you noted, marked
derangements of T-cell function have been reported in patients
with idiopathic minimal-change disease and in those with focal
sclerosis. These derangements reverse if treatment induces a
remission. One could speculate that the patients with secondary
forms of focal sclerosis mediated by hemodynamic abnormalities
might not share these T-cell abnormalities. Have you examined
this possibility?
DR. D'AOATI: We have not. However, with the newly described
assays for a glomerular "permeability factor" described by Savin
[58, 59] and Dantal [65], we now have the means to test this
hypothesis in a systematic way in diverse forms of primary and
secondary FSGS.
DR. DONALD FEINFELD (Division of Nephrology, Nassau County
Medical Center): My understanding is that tubulo-interstitial le-
sions are common in all forms of focal sclerosis. In fact, I was
taught that if a biopsy from a patient with nephrotic syndrome
looks like minimal-change disease but contains tubulo-interstitial
lesions, one must look hard for evidence of focal sclerosis. Where
do tubulo-interstitial lesions fit into the picture of focal sclerosis?
DR. D'AGATI: I distinguish between two types of tubulo-
interstitial injury. One is the dependent tubular atrophy and
interstitial fibrosis that necessarily arise consequent to glomerular
obsolescence and nephron "drop out." My observations indicate
that in most patients with "classic" FSGS, the severity and
distribution of the tubulo-interstitial injury generally parallel the
number and distribution of sclerotic glomeruli; thus tubulo-
interstitial and glomerular injury likely are related phenomena. In
some examples of FSGS, however, the tubulo-interstitial injury
appears disproportionately severe for the degree of glomerulo-
sclerosis. In fact, in some cases the tubulo-interstitial injury is
quite diffuse and profound in the presence of more focal and mild
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glomerular alterations. In such cases, I believe that other mech-
anisms of tubulo-interstitial injury, which I have alluded to, are
operative. The role of proteinuria per se in the development of
tubulo-interstitial injury is only beginning to receive adequate
attention. Finally, we should not forget that, in some cases of
FSGS, a renal biopsy finding of disproportinately severe tubulo-
interstititial injury can reflect the development of superimposed
renal vein thrombosis.
DR. COHEN: I was also struck by the correlation between the
extent of interstitial disease and the severity of the renal failure in
patients with focal sclerosis. A similar relationship has been noted
in lupus nephritis. Indeed, as I recall, de Wardener suggested
many years ago that clinical outcomes in all forms of glomerulo-
nephritis correlate much more strongly with the severity of
interstitial disease than with the severity of glomerular involve-
ment [133]. How general is this relationship?
DR. D'AGATI: You are right. It is a general observation that
renal function correlates better with tubulo-interstitial than gb-
merular alterations in virtually every primary glomerular disease,
and FSGS is no exception to this rule.
DR. COHEN: Your hypothesis that filtered proteins somehow
might be toxic to the tubulo-interstitium recalls the classic obser-
vations that led to the term "lipoid nephrosis," the old name for
nephrotic syndrome. Vacuolar changes in the tubules are often
the most dominant histologic finding in patients with heavy
proteinuria. Is there any relation between this finding and the kind
of injury that you're talking about?
DR. D'AGATI: No, I do not believe there is a direct relationship.
Tubular vacuolar change, a reversible lesion caused by increased
lipid and protein reabsorption by the proximal tubule, is com-
monly observed in any state of glomerular proteinuria, In mini-
mal-change disease, it typically occurs without accompanying
interstitial fibrosis or tubular atrophy. However, some experimen-
tal evidence suggests that the catabolism of lipid-rich albumin by
tubular cells can generate chemotactins that attract mononuclear
cells to the interstitium and promote the release of fibrogenic
cytokines [115]. We do not know enough about the critical levels,
duration, and selectivity of the proteinuria that place a patient at
risk for the development of irreversible tubulo-interstitial disease.
Yet we do know that unremitting severe proteinuria is a poor
prognostic feature in many primary glomerular diseases including,
for example, membranous glomerulopathy and membranoprolif-
erative glomerulonephritis as well as FSGS.
DR. RICHARD SCHWARZ (Division Head, General Medicine, State
Universily of New York at Stony Brook): As the incidence of the
idiopathic variety of focal sclerosis increases, and as the incidence
of HIV-associated nephropathy increases, heroin-associated focal
sclerosis is apparently decreasing. Does this observation reflect
the availability of purer, less contaminated, and hence less-
pathogenetic heroin on the street, or are patients developing HIV
nephropathy before they have a chance to acquire heroin ne-
phropathy?
DR. D'AGATI: Although I did not present the data, we have
looked at this issue in our own biopsy population. We saw a peak
of heroin nephropathy in the mid-1970s to early 1980s, with a
subsequent sharp decline that paralleled the emergence of HIV-
associated nephropathy in the mid-1980s. Currently heroin ne-
phropathy is nearly extinct. Of course this question hinges on
semantic issues; any FSGS developing in an intravenous drug
abuser who is HIV-positive by convention is termed HIV-associ-
ated nephropathy. We cannot be sure to what extent heroin abuse
per se in these patients might have played a pathogenetic role in
the development of FSGS. Clearly, however, the incidence of
heroin nephropathy, defined as FSGS in the HIV-negative intra-
venous drug abuser, has declined dramatically in the New York
City area. Among the 600 renal biopsies we receive annually, I
currently diagnose only 1 or 2 cases per year.
DR. GEORGE KALOYANIDES (Division of Nephrology, State Uni-
versity of New York at Stony Brook): Nephrotic syndrome second-
ary to focal segmental glomeruloscierosis has been classified as a
steroid-resistant disease. A recent report, however, suggests that
as many as 40% of such patients respond to steroid therapy [134].
Are any clues discernible on renal biopsy specimens that identify
patients who are likely to respond to steroid therapy?
DR. D'AGA'n: Unfortunately, no morphologic features allow us
to predict the subset of patients with idiopathic FSGS who will
respond to therapy. On the other hand, certain biopsy features
such as advanced interstitial fibrosis [124] predict a poor outcome.
As I mentioned in my talk, our center and the group from the
University of North Carolina at Chapel Hill have observed a lower
response to therapy and greater likelihood of progression to renal
failure in patients with collapsing FSGS [12, 13]. I hope that in the
future we will be able to supplement conventional renal biopsy
with assays for serum permeability factors to design more rational,
individualized therapy. I cannot emphasize enough the impor-
tance of complete renal biopsy workup and thorough review of the
clinical history to exclude secondary forms of FSGS in which
immunosuppressive therapy is contraindicated.
DR. COHEN: Are there animal models of obesity in which
secondary focal sclerosis occurs?
DR. D'AGATI: Yes, a model of glomerulosclerosis has been
established in Wistar rats [135] and Zucker obese rats [136] by the
administration of dietary lipids. In this model, treatment of the
hyperlipidemia has been reported to attenuate the development
of glomerular sclerosis [136].
DR. COHEN: Did you say that patients with idiopathic focal
sclerosis who also had large gbomeruli tended to have a different
clinical course? If so, does this observation raise the possibility
that those patients might, in fact, have a secondary, perhaps
hemodynamically mediated, form of the disease that led to the
glomerular hypertrophy?
DR. D'AGATI: I did not state that patients with idiopathic FSGS
and large glomeruli have a different clinical course from those
without glomerulomegaly. I did show evidence that patients with
glomerulomegaly and apparent minimal-change disease are at
greater risk for progression to FSGS than those without gbomeru-
lomegaly [34]. I know of only one study addressing the prognostic
importance of glomerular hypertrophy per se in idiopathic FSGS
[137]. In this study of only 12 patients with idiopathic FSGS, mean
glomerular diameter independent of body surface area was sta-
tistically significantly greater in the 6 with rapid progression to
chronic renal failure (P < .003). In this study, however, it could
not be determined whether the glomerular hypertrophy was a
pre-existing condition or a compensatory phenomenon following
loss of functioning nephrons. Important questions for the future
will be whether the patients with idiopathic FSGS and gbomeru-
lomegaly are more likely to benefit from therapy with ACE
inhibitors, angiotensin-Il-receptor antagonists, or other maneu-
vers designed to block the hypertrophic response.
DR. COHEN: Idiopathic just means we don't yet know what the
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real pathogenesis is. Could those individuals have a hemodynamic
alteration that hasn't been identified yet?
DR. D'AGATI: I think it is more likely that patients with
idiopathic FSGS in whom glomeruli are enlarged have glomeru-
lomegaly on a congenital basis rather than as an acquired
phenomenon related to hemodynamic stresses. I have already
alluded to data by Merlet-Benichou indicating that varying sever-
ities of oligomeganephronia can occur on a developmental basis in
the kidneys of low-birth-weight infants [74]. The racial predilec-
tion to FSGS among African-Americans might be due in part to
such developmental phenomena or alternatively to yet-unidenti-
fied genetic factors [73].
DR. LEONARD MEISELAS (Department of Medicine, State Univer-
sity of New York at Stony Brook): Do patients with acromegaly,
who have big kidneys and possibly hyperfiltration, develop this
lesion?
DR. D'AGATI: We know that growth hormone plays a role in the
development of glomerulosclerosis in animal models. Doi et a!
reported the development of diffuse glomerulosclerosis in mice
transgenic for growth hormone but not insulin-like growth fac-
tor-i (IGF-1) [138]. Moreover, the glomeruli of the growth-
hormone-transgenic mice were larger as a function of either
kidney weight or body weight than were those of littermate
controls, The severity of glomeruloscierosis also correlated with
glomerular size and protein excretion. A similar relationship
between glomerular size and glomeruloscierosis has been demon-
strated by Yoshida and colleagues in a new mutant strain of
Sprague-Dawley rats with a selective genetic defect in the growth
hormone gene [139]. A role for endogenous growth hormone in
the development of glomeruloscierosis was supported by the
observation that the hypertrophic response to subtotal nephrec-
tomy and the subsequent development of glomerulosclerosis was
markedly attenuated in the growth-hormone-deficient rats.
In view of these experimental data, it is surprising that there is
no clear association between gigantism and the development of
glomerulosclerosis in humans. Certainly in acromegaly, organo-
megaly affects many organs, including the kidney. Histologic
studies have revealed large glomeruli and tubules and thickening
of the capillary basement membranes [140]. To the best of my
knowledge, however, an increased incidence of chronic renal
failure has not been reported. Now that recombinant growth
hormone is being used therapeutically in patients with chronic
renal failure, it has been a matter of concern whether such therapy
accelerates the development of glomerulosclerosis. Studies both
in pediatric and adult patients with chronic renal failure have
shown no effect of the administration of chronic growth hormone
on GFR [141, 142], although one study noted a decreased GFR in
some pediatric renal transplant recipients [143].
DR. COHEN: You suggested that the distinction between the
collapsing and the cellular varieties of focal sclerosis was clear-cut.
Are there cases in which the distinction is not so clear, in which
you see elements of both?
DR. D'AGATI: Yes, in some cases the distinction between these
morphologic variants is difficult and there can be overlapping
features. In fact, on reviewing the original description of cellular
FSGS by Schwartz and Lewis [8], I noticed one figure depicting
what I would now classi1' as collapsing FSGS. A source of
confusion comes from the common occurrence of visceral cell,
that is, extracapillary, hyperplasia in the collapsing variant of
FSGS. In the classification I have proposed, I reserve the term
"cellular" FSGS for those cases with prominent endocapillary
hypercellularity, a feature not observed in the collapsing form.
Da. COHEN: 'Sounds like we should stay tuned.
Reprint requests to Dr. V. D'Agaft, Director, Renal Pathology Laboratoiy,
College of Physicians and Surgeons of Columbia University, 630 West 168th
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